Highlights from the American Society of Hematology meeting
This article was originally published in Scrip
Executive Summary
Datamonitor Healthcare's Aine Slowey takes an in-depth look at the highlights of this week's annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana, focussing on Roche/Biogen Idec's Gazyva, Celgene's Revlimid and Gilead's idelalisib.